Royce & Associates
PRME icon

Royce & Associates’s Prime Medicine PRME Stock Holding History

Royce & Associates’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-60,999
Closed -$314K – 893
2024
Q2 		$314K Buy
60,999
+14,785
+32% +$89.6K ﹤0.01% 823
2024
Q1 		$323K Buy
46,214
+6,377
+16% +$48.4K ﹤0.01% 814
2023
Q4 		$353K Buy
+39,837
New +$307K ﹤0.01% 814

Other funds holding PRME

Alphabet Inc
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Royce & Associates's PRME Position: Q3 2024 in Review

Royce & Associates sold out of Prime Medicine (PRME) in Q3 2024, closing a stake of 60,999 shares — an estimated $314K sold.

Royce & Associates first reported a position in PRME in Q4 2023 and held it in 3 quarters. The position peaked at $353K in Q4 2023. 116 funds tracked by Wall St. Rank hold PRME as of Q3 2024.

  • Royce & Associates reported no remaining Prime Medicine position as of Q3 2024 after selling out during the quarter.
  • Royce & Associates sold 60,999 Prime Medicine shares in Q3 2024, an estimated $314K.
  • Royce & Associates first reported a position in Prime Medicine in Q4 2023 and held it in 3 quarters.
  • Royce & Associates's Prime Medicine position peaked at $353K in Q4 2023.
  • 116 funds tracked by Wall St. Rank held Prime Medicine as of Q3 2024.

Based on Royce & Associates's 13F filing for Q3 2024, filed 6 Nov 2024.